Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Respiratory Treatment Guidelines

Introduction to Respiratory Treatment

  • Respiratory treatment guidelines are established by various medical societies, including the American College of Allergy and Clinical Immunology, the American Thoracic Society, the British Thoracic Society, and the European Respiratory Society, to provide evidence-based recommendations for the management of respiratory conditions 1, 2, 3

Medication Dosage and Administration

  • For adults with mucus, congestion, and wheezing, guaifenesin should be dosed at 200-400 mg orally every 4 hours (immediate-release) or 600-1200 mg every 12 hours (extended-release), while DuoNeb (ipratropium bromide 0.5 mg/albuterol 2.5 mg) should be administered via nebulizer every 20 minutes for 3 doses initially, then every 4-6 hours as needed, as recommended by the American College of Allergy and Clinical Immunology 1, 2, 4
  • The dosage of Ipratropium Bromide is 250-500 μg four times daily, particularly effective in COPD, as stated by the European Respiratory Society and the British Thoracic Society 3
  • Salbutamol dosages are 2.5-5 mg for adults and 0.15 mg/kg for children, with indications including severe acute asthma, COPD exacerbations, and chronic persistent asthma, as recommended by the British Thoracic Society 3
  • Terbutaline dosages are 5-10 mg for adults and 0.3 mg/kg for children, with similar indications to salbutamol, and precautions should be taken in patients with known hypersensitivity or cardiac disorders, as recommended by the British Thoracic Society 3
  • Ribavirine is used for severe bronchiolitis, with a dosage of 20 mg/ml for 12-18 hours/day over 3-7 days, as recommended by the British Thoracic Society 3
  • Budesonide may help reduce oral corticosteroid requirements in steroid-dependent asthma, with patients with severe persistent asthma considered for up to 1 mg twice daily, as recommended by the British Thoracic Society 3

Medication Safety and Precautions

  • DuoNeb should be used with caution in patients with cardiovascular disorders, hyperthyroidism, diabetes mellitus, or narrow-angle glaucoma, as recommended by the American College of Allergy and Clinical Immunology 2
  • Ipratropium Bromide should be used with a mouthpiece to reduce eye complications, as recommended by the American Thoracic Society and the British Thoracic Society 3
  • Precautions should be taken in patients with known hypersensitivity or cardiac disorders when using Terbutaline, as recommended by the British Thoracic Society 3

Mechanism of Action

  • Guaifenesin works as an expectorant by loosening phlegm and bronchial secretions, increasing expectorated sputum volume, decreasing sputum viscosity, and making coughs more productive, with clinical evidence supporting its effectiveness for productive cough, as recommended by the American College of Allergy and Clinical Immunology 1
  • Ipratropium Bromide is effective in COPD, often combined with beta-agonists, as stated by the European Respiratory Society and the British Thoracic Society 3

Nebulizer Use and Maintenance

  • Nebulizers should be cleaned after each use and replaced every three months, as recommended by the Global Initiative for Chronic Obstructive Lung Disease and the British Thoracic Society 3
  • The source of gas for nebulizers can be an electric compressor or compressed air (6-8 L/min), with a volume of 2.0-4.5 ml in the nebulizer chamber, and a duration of 10 minutes sufficient for bronchodilators, as per the British Thoracic Society guidelines 3

Assessment and Monitoring

  • Assess severity markers, including inability to complete sentences in one breath, respiratory rate ≥25/min, heart rate ≥110/min, and PEF ≤50% predicted normal or best, as recommended by the British Thoracic Society 3
  • Monitor treatment response by measuring peak flow before and 30 minutes after treatment, and continue nebulized treatments until PEF >75% predicted normal or best, according to the British Thoracic Society 3
  • For chronic use assessment, document clinical benefit with a home trial, and monitor peak flow twice daily for two weeks on standard treatment and two weeks on nebulized treatment, with an increase of ≥15% in mean baseline peak flow indicating benefit, as recommended by the British Thoracic Society 3
  • Once stabilized, transition patients from nebulized treatments to hand-held inhalers, and observe for 24-48 hours after switching to ensure stability, as recommended by the British Thoracic Society 3

Initial Treatment

  • Initial treatment for adults includes nebulized β-agonist (5 mg salbutamol or 10 mg terbutaline) plus ipratropium (500 μg), with oxygen used as the carrier gas if possible, as per the British Thoracic Society guidelines 3
  • For children, treatment consists of high-flow humidified oxygen and nebulized bronchodilator, with signs of severity including inability to speak/feed, respiratory rate >50/min, and pulse >140/min, as recommended by the British Thoracic Society 3
  • Combined nebulized treatment (β-agonist with ipratropium bromide 500 μg) every 4-6 hours is particularly beneficial for very severe exacerbations, according to the British Thoracic Society 3